Skip to main content
Top
Published in: Investigational New Drugs 6/2014

01-12-2014 | PRECLINICAL STUDIES

Targeting polo-like kinase 1 by NMS-P937 in osteosarcoma cell lines inhibits tumor cell growth and partially overcomes drug resistance

Authors: Valeria Sero, Elisa Tavanti, Serena Vella, Claudia Maria Hattinger, Marilù Fanelli, Francesca Michelacci, Rogier Versteeg, Barbara Valsasina, Beth Gudeman, Piero Picci, Massimo Serra

Published in: Investigational New Drugs | Issue 6/2014

Login to get access

Summary

Background Polo-like kinase 1 (PLK1) has emerged as a prognostic factor in various neoplasms, but only scarce data have been reported for high-grade osteosarcoma (OS). In this study, we assessed PLK1 expression and the efficacy of PLK1 inhibitor NMS-P937 in OS. Methods PLK1 expression was assessed on 21 OS clinical samples and on a panel of human OS cell lines. In vitro efficacy of NMS-P937 was evaluated on nine drug-sensitive and six drug-resistant human OS cell lines, either as single agent or in combination with the drugs used in chemotherapy for OS. Results PLK1 expression was higher in OS clinical samples and cell lines compared to normal human tissue. A higher PLK1 expression at diagnosis appeared to be associated with an unfavourable clinical outcome. PLK1 silencing produced growth inhibition, cell cycle retardation and apoptosis induction in human OS cell lines. NMS-P937 proved to be highly active in both drug-sensitive and drug-resistant cell lines, with the only exception of ABCB1-overexpressing, Doxorubicin (DX)-resistant variants. However, in these cells, the association of NMS-P937 with DX was able to revert DX-resistance by negatively interfering with ABCB1 transport activity. NMS-P937 was also able to decrease clonogenic and migration ability of human OS cell lines. Conclusion PLK1 can be proposed as a new candidate target for OS. Targeting PLK1 in OS with NMS-P937 in association with conventional chemotherapeutic drugs may be a new interesting therapeutic option, since this approach has proved to be active against drug resistant cells.
Appendix
Available only for authorised users
Literature
4.
go back to reference Gray PJ Jr, Bearss DJ, Han H, Nagle R, Tsao MS, Dean N, Von Hoff DD (2004) Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer. Mol Cancer Ther 3(5):641–646PubMed Gray PJ Jr, Bearss DJ, Han H, Nagle R, Tsao MS, Dean N, Von Hoff DD (2004) Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer. Mol Cancer Ther 3(5):641–646PubMed
5.
go back to reference Guan R, Tapang P, Leverson JD, Albert D, Giranda VL, Luo Y (2005) Small interfering RNA-mediated Polo-like kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals. Cancer Res 65(7):2698–2704. doi:10.1158/0008-5472.CAN-04-2131 CrossRefPubMed Guan R, Tapang P, Leverson JD, Albert D, Giranda VL, Luo Y (2005) Small interfering RNA-mediated Polo-like kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals. Cancer Res 65(7):2698–2704. doi:10.​1158/​0008-5472.​CAN-04-2131 CrossRefPubMed
6.
go back to reference Spankuch B, Matthess Y, Knecht R, Zimmer B, Kaufmann M, Strebhardt K (2004) Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1. J Natl Cancer Inst 96(11):862–872CrossRefPubMed Spankuch B, Matthess Y, Knecht R, Zimmer B, Kaufmann M, Strebhardt K (2004) Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1. J Natl Cancer Inst 96(11):862–872CrossRefPubMed
8.
go back to reference Yamaguchi U, Honda K, Satow R, Kobayashi E, Nakayama R, Ichikawa H, Shoji A, Shitashige M, Masuda M, Kawai A, Chuman H, Iwamoto Y, Hirohashi S, Yamada T (2009) Functional genome screen for therapeutic targets of osteosarcoma. Cancer Sci 100(12):2268–2274. doi:10.1111/j.1349-7006.2009.01310.x CrossRefPubMed Yamaguchi U, Honda K, Satow R, Kobayashi E, Nakayama R, Ichikawa H, Shoji A, Shitashige M, Masuda M, Kawai A, Chuman H, Iwamoto Y, Hirohashi S, Yamada T (2009) Functional genome screen for therapeutic targets of osteosarcoma. Cancer Sci 100(12):2268–2274. doi:10.​1111/​j.​1349-7006.​2009.​01310.​x CrossRefPubMed
10.
go back to reference Morales AG, Brassesco MS, Pezuk JA, Oliveira JC, Montaldi AP, Sakamoto-Hojo ET, Scrideli CA, Tone LG (2011) BI 2536-mediated PLK1 inhibition suppresses HOS and MG-63 osteosarcoma cell line growth and clonogenicity. Anticancer Drugs 22(10):995–1001. doi:10.1097/CAD.0b013e32834a16d4 PubMed Morales AG, Brassesco MS, Pezuk JA, Oliveira JC, Montaldi AP, Sakamoto-Hojo ET, Scrideli CA, Tone LG (2011) BI 2536-mediated PLK1 inhibition suppresses HOS and MG-63 osteosarcoma cell line growth and clonogenicity. Anticancer Drugs 22(10):995–1001. doi:10.​1097/​CAD.​0b013e32834a16d4​ PubMed
13.
go back to reference Ottaviano L, Schaefer KL, Gajewski M, Huckenbeck W, Baldus S, Rogel U, Mackintosh C, de Alava E, Myklebost O, Kresse SH, Meza-Zepeda LA, Serra M, Cleton-Jansen AM, Hogendoorn PC, Buerger H, Aigner T, Gabbert HE, Poremba C (2010) Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort. Genes Chromosomes Cancer 49(1):40–51. doi:10.1002/gcc.20717 CrossRefPubMed Ottaviano L, Schaefer KL, Gajewski M, Huckenbeck W, Baldus S, Rogel U, Mackintosh C, de Alava E, Myklebost O, Kresse SH, Meza-Zepeda LA, Serra M, Cleton-Jansen AM, Hogendoorn PC, Buerger H, Aigner T, Gabbert HE, Poremba C (2010) Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort. Genes Chromosomes Cancer 49(1):40–51. doi:10.​1002/​gcc.​20717 CrossRefPubMed
14.
15.
go back to reference Serra M, Reverter-Branchat G, Maurici D, Benini S, Shen JN, Chano T, Hattinger CM, Manara MC, Pasello M, Scotlandi K, Picci P (2004) Analysis of dihydrofolate reductase and reduced folate carrier gene status in relation to methotrexate resistance in osteosarcoma cells. Ann Oncol 15(1):151–160CrossRefPubMed Serra M, Reverter-Branchat G, Maurici D, Benini S, Shen JN, Chano T, Hattinger CM, Manara MC, Pasello M, Scotlandi K, Picci P (2004) Analysis of dihydrofolate reductase and reduced folate carrier gene status in relation to methotrexate resistance in osteosarcoma cells. Ann Oncol 15(1):151–160CrossRefPubMed
16.
go back to reference Serra M, Scotlandi K, Manara MC, Maurici D, Lollini PL, De Giovanni C, Toffoli G, Baldini N (1993) Establishment and characterization of multidrug-resistant human osteosarcoma cell lines. Anticancer Res 13(2):323–329PubMed Serra M, Scotlandi K, Manara MC, Maurici D, Lollini PL, De Giovanni C, Toffoli G, Baldini N (1993) Establishment and characterization of multidrug-resistant human osteosarcoma cell lines. Anticancer Res 13(2):323–329PubMed
17.
go back to reference Molenaar JJ, Koster J, Ebus ME, van Sluis P, Westerhout EM, de Preter K, Gisselsson D, Ora I, Speleman F, Caron HN, Versteeg R (2012) Copy number defects of G1-cell cycle genes in neuroblastoma are frequent and correlate with high expression of E2F target genes and a poor prognosis. Genes Chromosomes Cancer 51(1):10–19. doi:10.1002/gcc.20926 CrossRefPubMed Molenaar JJ, Koster J, Ebus ME, van Sluis P, Westerhout EM, de Preter K, Gisselsson D, Ora I, Speleman F, Caron HN, Versteeg R (2012) Copy number defects of G1-cell cycle genes in neuroblastoma are frequent and correlate with high expression of E2F target genes and a poor prognosis. Genes Chromosomes Cancer 51(1):10–19. doi:10.​1002/​gcc.​20926 CrossRefPubMed
19.
go back to reference Hattinger CM, Stoico G, Michelacci F, Pasello M, Scionti I, Remondini D, Castellani GC, Fanelli M, Scotlandi K, Picci P, Serra M (2009) Mechanisms of gene amplification and evidence of coamplification in drug-resistant human osteosarcoma cell lines. Genes Chromosomes Cancer 48(4):289–309. doi:10.1002/gcc.20640 CrossRefPubMed Hattinger CM, Stoico G, Michelacci F, Pasello M, Scionti I, Remondini D, Castellani GC, Fanelli M, Scotlandi K, Picci P, Serra M (2009) Mechanisms of gene amplification and evidence of coamplification in drug-resistant human osteosarcoma cell lines. Genes Chromosomes Cancer 48(4):289–309. doi:10.​1002/​gcc.​20640 CrossRefPubMed
21.
go back to reference Robey RW, Shukla S, Finley EM, Oldham RK, Barnett D, Ambudkar SV, Fojo T, Bates SE (2008) Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)). Biochem Pharmacol 75(6):1302–1312. doi:10.1016/j.bcp.2007.12.001 PubMedCentralCrossRefPubMed Robey RW, Shukla S, Finley EM, Oldham RK, Barnett D, Ambudkar SV, Fojo T, Bates SE (2008) Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)). Biochem Pharmacol 75(6):1302–1312. doi:10.​1016/​j.​bcp.​2007.​12.​001 PubMedCentralCrossRefPubMed
23.
go back to reference Dai X, Ma W, He X, Jha RK (2011) Review of therapeutic strategies for osteosarcoma, chondrosarcoma, and Ewing’s sarcoma. Med Sci Monit 17(8):RA177–190PubMedCentralCrossRefPubMed Dai X, Ma W, He X, Jha RK (2011) Review of therapeutic strategies for osteosarcoma, chondrosarcoma, and Ewing’s sarcoma. Med Sci Monit 17(8):RA177–190PubMedCentralCrossRefPubMed
26.
go back to reference Hu K, Lee C, Qiu D, Fotovati A, Davies A, Abu-Ali S, Wai D, Lawlor ER, Triche TJ, Pallen CJ, Dunn SE (2009) Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas. Mol Cancer Ther 8(11):3024–3035. doi:10.1158/1535-7163.MCT-09-0365 PubMedCentralCrossRefPubMed Hu K, Lee C, Qiu D, Fotovati A, Davies A, Abu-Ali S, Wai D, Lawlor ER, Triche TJ, Pallen CJ, Dunn SE (2009) Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas. Mol Cancer Ther 8(11):3024–3035. doi:10.​1158/​1535-7163.​MCT-09-0365 PubMedCentralCrossRefPubMed
27.
go back to reference Beria I, Bossi RT, Brasca MG, Caruso M, Ceccarelli W, Fachin G, Fasolini M, Forte B, Fiorentini F, Pesenti E, Pezzetta D, Posteri H, Scolaro A, Re Depaolini S, Valsasina B (2011) NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor. Bioorg Med Chem Lett 21(10):2969–2974. doi:10.1016/j.bmcl.2011.03.054 CrossRefPubMed Beria I, Bossi RT, Brasca MG, Caruso M, Ceccarelli W, Fachin G, Fasolini M, Forte B, Fiorentini F, Pesenti E, Pezzetta D, Posteri H, Scolaro A, Re Depaolini S, Valsasina B (2011) NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor. Bioorg Med Chem Lett 21(10):2969–2974. doi:10.​1016/​j.​bmcl.​2011.​03.​054 CrossRefPubMed
28.
go back to reference Valsasina B, Beria I, Alli C, Alzani R, Avanzi N, Ballinari D, Cappella P, Caruso M, Casolaro A, Ciavolella A, Cucchi U, De Ponti A, Felder E, Fiorentini F, Galvani A, Gianellini LM, Giorgini ML, Isacchi A, Lansen J, Pesenti E, Rizzi S, Rocchetti M, Sola F, Moll J (2012) NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies. Mol Cancer Ther 11(4):1006–1016. doi:10.1158/1535-7163.MCT-11-0765 CrossRefPubMed Valsasina B, Beria I, Alli C, Alzani R, Avanzi N, Ballinari D, Cappella P, Caruso M, Casolaro A, Ciavolella A, Cucchi U, De Ponti A, Felder E, Fiorentini F, Galvani A, Gianellini LM, Giorgini ML, Isacchi A, Lansen J, Pesenti E, Rizzi S, Rocchetti M, Sola F, Moll J (2012) NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies. Mol Cancer Ther 11(4):1006–1016. doi:10.​1158/​1535-7163.​MCT-11-0765 CrossRefPubMed
29.
go back to reference Casolaro A, Golay J, Albanese C, Ceruti R, Patton V, Cribioli S, Pezzoni A, Losa M, Texido G, Giussani U, Marchesi F, Amboldi N, Valsasina B, Bungaro S, Cazzaniga G, Rambaldi A, Introna M, Pesenti E, Alzani R (2013) The Polo-Like Kinase 1 (PLK1) inhibitor NMS-P937 is effective in a new model of disseminated primary CD56+ acute monoblastic leukaemia. PLoS One 8(3):e58424. doi:10.1371/journal.pone.0058424 PubMedCentralCrossRefPubMed Casolaro A, Golay J, Albanese C, Ceruti R, Patton V, Cribioli S, Pezzoni A, Losa M, Texido G, Giussani U, Marchesi F, Amboldi N, Valsasina B, Bungaro S, Cazzaniga G, Rambaldi A, Introna M, Pesenti E, Alzani R (2013) The Polo-Like Kinase 1 (PLK1) inhibitor NMS-P937 is effective in a new model of disseminated primary CD56+ acute monoblastic leukaemia. PLoS One 8(3):e58424. doi:10.​1371/​journal.​pone.​0058424 PubMedCentralCrossRefPubMed
30.
go back to reference Fink J, Sanders K, Rippl A, Finkernagel S, Beckers TL, Schmidt M (2007) Cell type-- dependent effects of Polo-like kinase 1 inhibition compared with targeted polo box interference in cancer cell lines. Mol Cancer Ther 6(12 Pt 1):3189–3197. doi:10.1158/1535-7163.MCT-07-0048 CrossRefPubMed Fink J, Sanders K, Rippl A, Finkernagel S, Beckers TL, Schmidt M (2007) Cell type-- dependent effects of Polo-like kinase 1 inhibition compared with targeted polo box interference in cancer cell lines. Mol Cancer Ther 6(12 Pt 1):3189–3197. doi:10.​1158/​1535-7163.​MCT-07-0048 CrossRefPubMed
31.
go back to reference Louwen F, Yuan J (2013) Battle of the eternal rivals: restoring functional p53 and inhibiting Polo-like kinase 1 as cancer therapy. Oncotarget 4(7):958–971PubMedCentralCrossRefPubMed Louwen F, Yuan J (2013) Battle of the eternal rivals: restoring functional p53 and inhibiting Polo-like kinase 1 as cancer therapy. Oncotarget 4(7):958–971PubMedCentralCrossRefPubMed
32.
34.
go back to reference Han DP, Zhu QL, Cui JT, Wang PX, Qu S, Cao QF, Zong YP, Feng B, Zheng MH, Lu AG (2012) Polo-like kinase 1 is overexpressed in colorectal cancer and participates in the migration and invasion of colorectal cancer cells. Med Sci Monit 18(6):BR237–246PubMedCentralCrossRefPubMed Han DP, Zhu QL, Cui JT, Wang PX, Qu S, Cao QF, Zong YP, Feng B, Zheng MH, Lu AG (2012) Polo-like kinase 1 is overexpressed in colorectal cancer and participates in the migration and invasion of colorectal cancer cells. Med Sci Monit 18(6):BR237–246PubMedCentralCrossRefPubMed
Metadata
Title
Targeting polo-like kinase 1 by NMS-P937 in osteosarcoma cell lines inhibits tumor cell growth and partially overcomes drug resistance
Authors
Valeria Sero
Elisa Tavanti
Serena Vella
Claudia Maria Hattinger
Marilù Fanelli
Francesca Michelacci
Rogier Versteeg
Barbara Valsasina
Beth Gudeman
Piero Picci
Massimo Serra
Publication date
01-12-2014
Publisher
Springer US
Published in
Investigational New Drugs / Issue 6/2014
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-014-0158-6

Other articles of this Issue 6/2014

Investigational New Drugs 6/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine